• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Bruker Announces Date and Time of Fourth Quarter 2024 Earnings Release and Webcast

    2/7/25 7:00:00 AM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $BRKR alert in real time by email

    Bruker Corporation (NASDAQ:BRKR) today announced it will report fourth quarter and fiscal year 2024 financial results before market opening on Thursday, February 13, 2025. The Company will host a conference call and webcast at 8:30 a.m. Eastern Standard Time to discuss the results and current business trends.

    To listen to the webcast, investors can go to https://ir.bruker.com and click on the "Q4 2024 Earnings Webcast" hyperlink in the "Events & Presentations" section. A slide presentation will be referenced during the webcast and will be posted to the Company's website shortly before the webcast begins.

    Investors can also listen to the earnings webcast via telephone by dialing 1-888-437-2685 (U.S. toll free) or +1-412-317-6702 (international) and referencing "Bruker's Fourth Quarter 2024 Earnings Conference Call".

    Bruker is enabling investors to pre-register for the earnings conference call so that they can expedite their entry into the call and avoid the need to wait for a live operator. In order to pre-register for the call, investors can visit https://dpregister.com/sreg/10196649/fe70e3a396 and enter their contact information. Investors will then be issued a personalized phone number and PIN to dial into the live conference call. Individuals can pre-register any time prior to the start of the conference call on February 13.

    A telephone replay of the conference call will be available by dialing 1-877-344-7529 (U.S. toll free) or +1-412-317-0088 (international) and entering replay access code: 5344184. The replay will be available beginning one hour after the end of the conference call through March 13, 2025.

    About Bruker Corporation – Leader of the Post-Genomic Era (NASDAQ:BRKR)

    Bruker is enabling scientists and engineers to make breakthrough post-genomic discoveries and develop new applications that improve the quality of human life. Bruker's high performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity, and customer success in post-genomic life science molecular and cell biology research, in applied and biopharma applications, in microscopy and nanoanalysis, as well as in industrial and cleantech research, and next-gen semiconductor metrology in support of AI. Bruker offers differentiated, high value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. For more information, please visit www.bruker.com.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250207396426/en/

    Joe Kostka

    Director, Investor Relations

    Bruker Corporation

    T: +1 (978) 313-5800

    E: [email protected]

    Get the next $BRKR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BRKR

    DatePrice TargetRatingAnalyst
    5/22/2025$40.00Buy → Neutral
    Citigroup
    12/19/2024$72.00Buy
    Guggenheim
    12/10/2024$66.00Neutral
    UBS
    12/5/2024$60.00Sell → Neutral
    Goldman
    10/15/2024$75.00Overweight
    Barclays
    9/30/2024Outperform → Peer Perform
    Wolfe Research
    8/28/2024$78.00Overweight
    Wells Fargo
    6/3/2024$85.00Buy
    Jefferies
    More analyst ratings

    $BRKR
    SEC Filings

    See more
    • SEC Form SD filed by Bruker Corporation

      SD - BRUKER CORP (0001109354) (Filer)

      5/30/25 4:07:43 PM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Bruker Corporation filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - BRUKER CORP (0001109354) (Filer)

      5/29/25 4:34:19 PM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form DEFA14A filed by Bruker Corporation

      DEFA14A - BRUKER CORP (0001109354) (Filer)

      5/19/25 8:00:04 AM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $BRKR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Bruker Corporation

      SC 13G/A - BRUKER CORP (0001109354) (Subject)

      11/14/24 1:28:29 PM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Amendment: SEC Form SC 13G/A filed by Bruker Corporation

      SC 13G/A - BRUKER CORP (0001109354) (Subject)

      11/13/24 6:01:26 PM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Amendment: SEC Form SC 13G/A filed by Bruker Corporation

      SC 13G/A - BRUKER CORP (0001109354) (Subject)

      11/12/24 11:54:03 AM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $BRKR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Francis Laura was granted 4,498 shares (SEC Form 4)

      4 - BRUKER CORP (0001109354) (Issuer)

      5/19/25 5:08:26 PM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Director Ornell John A exercised 5,000 shares at a strike of $18.15, increasing direct ownership by 19% to 31,445 units (SEC Form 4)

      4 - BRUKER CORP (0001109354) (Issuer)

      5/14/25 4:12:44 PM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Director Linton William A exercised 10,000 shares at a strike of $24.00, increasing direct ownership by 21% to 58,723 units (SEC Form 4)

      4 - BRUKER CORP (0001109354) (Issuer)

      4/24/25 4:15:05 PM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $BRKR
    Leadership Updates

    Live Leadership Updates

    See more
    • Solis Agrosciences Names Crystal Winkeler Chief Business Officer to Drive Commercial Growth

      ST. LOUIS, April 23, 2025 (GLOBE NEWSWIRE) -- Solis Agrosciences, the trusted partner for high-quality AgTech research services, announced that it has hired Crystal Winkeler as Chief Business Officer. Winkeler will join Solis on May 1 to drive the company's commercial team and help lead efforts to develop and acquire new offerings. "Solis has assembled an impressive team, offerings, and customer base," said Winkeler. "I am thrilled to join the business at this important growth stage." "Crystal is a proven talent who is confident, capable, and credible in front of customers and stakeholders," said Charlie Bolten, CEO of Solis Agrosciences. "She is a huge addition and will help drive our c

      4/23/25 6:15:00 AM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Bruker Appoints Laura Francis to its Board of Directors

      Bruker Corporation (NASDAQ:BRKR) today announced that its Board of Directors has appointed Laura Francis to serve on its board as an independent director, effective as of February 18, 2025. Ms. Francis is also expected to join Bruker's Audit Committee as a financial expert after Bruker's annual shareholder meeting at the end of May 2025. Laura Francis is the Chief Executive Officer and a Board Member of SI-BONE, Inc. (NASDAQ:SIBN), a medical device company solving musculoskeletal disorders of the sacropelvic anatomy. She was previously the Chief Financial Officer and Chief Operating Officer of the company. Prior to joining SI-BONE, Ms. Francis held other executive and leadership roles with

      2/21/25 8:00:00 AM ET
      $BRKR
      $PGNY
      $SIBN
      $SWAV
      Biotechnology: Laboratory Analytical Instruments
      Industrials
      Misc Health and Biotechnology Services
      Health Care
    • Biognosys and Alamar Biosciences Forge Strategic Partnership in Proteomics to Advance Biopharma and Precision Medicine Research

      Strategic partnership expands Biognosys' services to include Alamar's NULISA assays as well as joint scientific research in biofluid-based proteomicsComplementary value of Biognosys' DIA-MS unbiased proteomics platform and Alamar's game-changing immunoassay platforms to be presented at the AACR 2024 Annual Meeting ZURICH, Switzerland and FREMONT, Calif., April 04, 2024 (GLOBE NEWSWIRE) -- Biognosys, a global leader in mass spectrometry-based proteomics, and Alamar Biosciences, Inc., a company powering precision proteomics to enable the earliest detection of disease, are pleased to announce a strategic partnership aimed at advancing scientific discovery in the field of biofluid proteomic

      4/4/24 8:11:00 AM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $BRKR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Bruker downgraded by Citigroup with a new price target

      Citigroup downgraded Bruker from Buy to Neutral and set a new price target of $40.00

      5/22/25 8:18:13 AM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Guggenheim initiated coverage on Bruker with a new price target

      Guggenheim initiated coverage of Bruker with a rating of Buy and set a new price target of $72.00

      12/19/24 7:30:10 AM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • UBS initiated coverage on Bruker with a new price target

      UBS initiated coverage of Bruker with a rating of Neutral and set a new price target of $66.00

      12/10/24 8:26:42 AM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $BRKR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Bruker Corporation to Present at the Jefferies Global Healthcare Conference

      Bruker Corporation (NASDAQ:BRKR) announced today that its senior leadership will participate in the Jefferies Global Healthcare Conference in New York City with a fireside chat presentation scheduled for Wednesday, June 4th, 2025 at 5:30 PM Eastern Time. A live audio webcast of the presentation will be available on the Investor Relations section of the Company's website at https://ir.bruker.com. A replay of the presentation will be posted in the "Events & Presentations" section of the Bruker Corporation Investor Relations website after the event and will be available for 30 days following the presentation. About Bruker Corporation – Leader of the Post-Genomic Era (NASDAQ:BRKR) Bruker

      5/30/25 4:31:00 PM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Bruker Launches Revolutionary timsOmniTM Mass Spectrometer

      Enabling Functional Proteoform Sequencing and Post-Translational Modification (PTM) Identification and Localization with Unprecedented Depth and Speed Beyond Protein Groups - Ushering in Era of ‘Proteoformics' with New Scientific Lamp-Post Shining Light on Functional, Therapeutic and Pathological Protein Isoforms Integrating timsTOF Speed and Performance with Novel Functionality of Omnitrap  timsOmni enables ‘Swiss Army Knife' flexibility in electron and collision induced ion fragmentation for next-gen proteoform insights to transform disease research, biologics development and advanced bioprocessing QC Unrivaled structural, sequencing and top-down dissociation flexibility with hi

      5/30/25 8:00:00 AM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Bruker Launches Novel timsMetabo™ Mass Spectrometer for Breakthrough 4D-Metabolomics and 4D-Lipidomics Sensitivity, Specificity and Annotation Confidence - at Speed, Depth, and Scale

      Game-changing sensitivity for TIMS-enabled small molecule analysis 4D LC-TIMS-MS/MS separations and CCS measurements at scale for unprecedented specificity and annotation confidence Introducing the ‘digital metabolome archive' for AI/ML scaling Novel TIMS Mobility Range Enhancement (MoRE) technology for m/z bandwidth Performance monitoring with QSee™ QC suite and cloud-based TwinScape™ for highest confidence in metabolomics - at speed and scale At the 73rd Conference on Mass Spectrometry and Allied Topics (ASMS), Bruker Corporation (NASDAQ:BRKR) launched timsMetabo, a peak-performance 4D-Metabolomics™ mass spectrometer delivering unprecedented sensitivity, separation power a

      5/30/25 7:00:00 AM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $BRKR
    Financials

    Live finance-specific insights

    See more
    • Bruker Announces Quarterly Dividend

      Bruker Corporation (NASDAQ:BRKR) today announced that its Board of Directors has approved payment of a quarterly cash dividend in the amount of $0.05 per share on the Company's common stock. The dividend will be paid on June 27, 2025 to stockholders of record as of June 16, 2025. About Bruker Corporation – Leader of the Post-Genomic Era (NASDAQ:BRKR) Bruker is enabling scientists and engineers to make breakthrough post-genomic discoveries and develop new applications that improve the quality of human life. Bruker's high-performance scientific instruments and high-value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microscop

      5/15/25 7:00:00 AM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Bruker Reports First Quarter 2025 Financial Results

       Q1 2025 revenues of $801.4 million, up 11.0% year-over-year; organic revenue up 2.9%, and constant-exchange rate (CER) revenue up 12.5%; Bruker Scientific Instrument (BSI) segment organic revenue up 5.1% Q1 2025 GAAP diluted EPS $0.11; non-GAAP diluted EPS $0.47, down 11.3% yoy on M&A headwinds Guidance on organic revenue and EPS adjusted for US policy changes and tariff headwinds. Updated FY 2025 guidance: Revenue $3.48 to $3.55 billion, up 3.5% to 5.5%, incl. organic growth of 0% to 2% Non-GAAP EPS $2.40 to $2.48, growth of 0% to 3% yoy Bruker Corporation (NASDAQ:BRKR) today announced financial results for its first quarter ended March 31, 2025. Frank H. Laukien, Bruker's

      5/7/25 7:00:00 AM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Bruker Announces First Quarter 2025 Preliminary Revenue

      Bruker Corporation (NASDAQ:BRKR) today announced preliminary revenue for the first quarter ended March 31, 2025, in a range of $795 million to $800 million, comparing favorably to the Company's earlier outlook and well ahead of consensus. This estimated range implies reported revenue growth of approximately 10% year-over-year, with low-double digit percentage constant exchange rate revenue growth. Bruker estimates non-GAAP organic revenue growth in the first quarter to be in the low-single digit percentages, with mid-single digit percentage organic revenue growth in the Bruker Scientific Instrument (BSI) segment, and a high-teens percentage organic revenue decline in the BEST segment, net

      4/11/25 8:00:00 AM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $BRKR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Accounting Officer Bures Thomas bought $23,698 worth of shares (500 units at $47.40), increasing direct ownership by 17% to 3,472 units (SEC Form 4)

      4 - BRUKER CORP (0001109354) (Issuer)

      3/11/25 4:11:27 PM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • PRESIDENT & CEO Laukien Frank H bought $1,018,330 worth of shares (20,000 units at $50.92), increasing direct ownership by 0.05% to 38,459,563 units (SEC Form 4)

      4 - BRUKER CORP (0001109354) (Issuer)

      2/19/25 4:23:26 PM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • PRESIDENT & CEO Laukien Frank H bought $5,014,069 worth of shares (100,000 units at $50.14), increasing direct ownership by 0.26% to 38,439,563 units (SEC Form 4)

      4 - BRUKER CORP (0001109354) (Issuer)

      11/19/24 4:07:19 PM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials